Oritavancin for acute bacterial skin and skin structure infections

Bibliography

• Suaya JA, Mera RM, Cassidy A, et al. Incidence and cost of hospitalizations associated with Staphylococcus aureus skin and soft tissue infections in the United States from 2001 through 2009. BMC Infect Dis 2014;14:296
   PubMed Web of Science ®Google Scholar
• Lee BY, Singh A, David MZ, et al. The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). Clin Microbiol Infect 2013;19(6):528-36
   PubMed Web of Science ®Google Scholar
• Garau J, Ostermann H, Medina J, et al. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010-2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect 2013;19(9):E377-85
   PubMed Web of Science ®Google Scholar
• LaPensee KT, Fan W, Wang Y. PIN22 economic burden of hospitalization with antibiotic treatment for Absssi in the United States: an analysis of the Premier Hospital database. Value Health 2012;15(4):A240-A41
   PubMed Web of Science ®Google Scholar
• Tice A. Oritavancin: a new opportunity for outpatient therapy of serious infections. Clin Infect Dis 2012;54(Suppl 3):S239-43
   PubMedGoogle Scholar
• Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003;36(4):429-39
   PubMed Web of Science ®Google Scholar
• Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, et al. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother 1998;42(2):199-209
   PubMedGoogle Scholar
• Fowler VGJr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355(7):653-65
   PubMed Web of Science ®Google Scholar
• Sharma M, Riederer K, Chase P, Khatib R. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Euro J Clin Microbiol Infect Dis 2008;27(6):433-7
   PubMedGoogle Scholar
• File TMJr, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis 2012;55(Suppl 3):S173-80
   PubMed Web of Science ®Google Scholar
• Chambers HF. Pharmacology and the treatment of complicated skin and skin-structure infections. N Engl J Med 2014;370(23):2238-9
   PubMed Web of Science ®Google Scholar
• Shorr AF, Lodise TP, Corey GR, et al. Analysis of the Phase 3 ESTABLISH Trials: tedizolid versus linezolid in acute bacterial skin and skin structure infection. Antimicrob Agents Chemother 2015;59(2):864-71
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Lentnek A, O’Riordan W, et al. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis 2014;14:289
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011;52(1):31-40
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008;46(11):1683-93
   PubMed Web of Science ®Google Scholar
• Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 2014;370(23):2169-79
   PubMed Web of Science ®Google Scholar
• Schwalbe RS, McIntosh AC, Qaiyumi S, et al. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob Agents Chemother 1996;40(10):2416-19
   PubMedGoogle Scholar
• Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis 2012;54(Suppl 3):S214-19
   PubMedGoogle Scholar
• Lin G, Pankuch G, Appelbaum PC, Kosowska-Shick K. Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents. Antimicrob Agents Chemother 2014;58(10):6251-4
   PubMedGoogle Scholar
• Saravolatz LD, Pawlak J, Johnson LB. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). Int J Antimicrob Agents 2010;36(1):69-72
   PubMedGoogle Scholar
• Mendes RE, Sader HS, Flamm RK, Jones RN. Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide. J Antimicrob Chemother 2014;69(6):1579-81
   PubMedGoogle Scholar
• Morrissey I, Seifert H, Canton R, et al. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and beta-haemolytic streptococci collected from western European countries in 2011. J Antimicrob Chemother 2013;68(1):164-7
   PubMedGoogle Scholar
• Ambrose PG, Drusano GL, Craig WA. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin Infect Dis 2012;54(Suppl 3):S220-8
   PubMed Web of Science ®Google Scholar
• McKay GA, Beaulieu S, Arhin FF, et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 2009;63(6):1191-9
   PubMed Web of Science ®Google Scholar
• Belley A, Arhin FF, Sarmiento I, et al. Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection. Antimicrob Agents Chemother 2013;57(1):205-11
   PubMedGoogle Scholar
• Rubino CM, Van Wart SA, Bhavnani SM, et al. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother 2009;53(10):4422-8
   PubMed Web of Science ®Google Scholar
• Rubino CM, Bhavnani SM, Moeck G, et al. Population pharmacokinetic (PPK) analysis for oritavancin (ORI) based on data from patients with acute bacterial skin and skin structure infections (ABSSSI) [abstract]. Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Washington D.C., USA; 2014
   Google Scholar
• Corey GR, Good S, Jiang H, et al. Single-dose oritavancin compared to 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin Structure infections; the SOLO II non-inferiority study. Clin Infect Dis 2015;60(2):254-62
   PubMed Web of Science ®Google Scholar
• Corey GR, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 2014;370(23):2180-90
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Owen JS, Loutit JS, et al. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis 2004;50(2):95-102
   PubMed Web of Science ®Google Scholar
• Dunbar LM, Milata J, McClure T, et al. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother 2011;55(7):3476-84
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Passarell JA, Owen JS, et al. Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006;50(3):994-1000
   PubMed Web of Science ®Google Scholar
• The Medicines Company. ORBACTIV™ (Oritavancin) [prescribing information]. Parsippany, NJ: 2014
   Google Scholar
• Arhin FF, Sarmiento I, Belley A, et al. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob Agents Chemother 2008;52(5):1597-603
   PubMed Web of Science ®Google Scholar
• Van Bambeke F. Renaissance of antibiotics against difficult infections: focus on oritavancin and new ketolides and quinolones. Ann Med 2014;1-18
   Google Scholar
• Van Bambeke F, Saffran J, Mingeot-Leclercq MP, Tulkens PM. Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation. Antimicrob Agents Chemother 2005;49(5):1695-700
   PubMedGoogle Scholar
• Baquir B, Lemaire S, Van Bambeke F, et al. Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin. Clin Infect Dis 2012;54(Suppl 3):S229-32
   PubMedGoogle Scholar
• Kaatz GW, Seo SM, Aeschlimann JR, et al. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1998;42(4):981-3
   PubMed Web of Science ®Google Scholar
• Xiong YQ, Yin L, Hady WA, et al. Efficacy of oritavancin (ORI), a lipoglycopeptide antibiotic, in a rat Staphylococcal aureus endocarditis (IE) model: microbiological and bioluminescent assessments. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America 46th Annual Meeting; Washington, DC; 2008
   Google Scholar
• Saleh-Mghir A, Lefort A, Petegnief Y, et al. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 1999;43(1):115-20
   PubMed Web of Science ®Google Scholar
• Lefort A, Saleh-Mghir A, Garry L, et al. Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis. Antimicrob Agents Chemother 2000;44(11):3017-21
   PubMed Web of Science ®Google Scholar
• Rodvold KA, McConeghy KW. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. Clin Infect Dis 2014;58(Suppl 1):S20-7
   PubMed Web of Science ®Google Scholar
• Mendes RE, Farrell DJ, Sader HS, et al. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010–13). J Antimicrob Chemother 2015;70(2):498-504
   PubMed Web of Science ®Google Scholar